The year in charts

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Ymmunobio and PSI win Innosuisse grant for treatment and diagnostic of solid tumors with radio pharmaceutical

Ymmunobio and the Paul Scherrer Institute win Innosuisse innovation grant to develop a radio pharmaceutical with YB’s proprietary YB-800
January 20, 2025

abc biopply & Preclina: Collaboration to improve predictiveness of preclinical studies

abc biopply AG, a pioneer innovator of humanized multi-organoid disease models, and Preclina Inc., a preclinical contract research organization specializing in immune related disorders and humanized animal models, have announced a strategic collaboration. The partnership between the two companies will provide customers with end-to-end project planning on humanized preclinical models from early in
January 18, 2025

Pharvaris' strategic priorities in 2025

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026 Study initiation of deucrictibant for the treatment of acquired
January 13, 2025

Sophia Genetics: ISO certifications for information security and privacy protection

Company reaffirms its commitment to information security and data protection in healthcare technology
January 9, 2025

SOTIO licenses fully human antibodies from Biocytogen

January 9, 2025